Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl-fucosyl type 1 chain - PubMed (original) (raw)
. 1988 Jul 1;48(13):3856-63.
Affiliations
- PMID: 2454154
Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl-fucosyl type 1 chain
R Kannagi et al. Cancer Res. 1988.
Abstract
The levels of carbohydrate antigens having epitopes consisting of type 1 chain (R----Gal beta 1----GlcNAc beta 1----3Gal beta 1----R) in the sera of patients with various malignant and nonmalignant disorders have been investigated with the use of three monoclonal antibodies, N-19-9, FH-7, and FH-9. Serum levels of 2----3 sialylated Lea antigen and 2----6 sialylated Lea antigen, defined respectively by antibodies N-19-9 and FH-7, were found to be frequently high in patients with cancer of the digestive system, particularly pancreatic cancer. High levels of 2----3,2----6 disialylated Lc4 antigen, defined by antibody FH-9, were less frequent in cancer patients when compared with the other two antigens. In patients with nonmalignant disorders, especially renal and autoimmune diseases, serum levels of the two type 1 chain antigens defined by FH-7 and FH-9 were more frequently high than that defined by N-19-9. Molecular weights and other general biochemical characteristics of serum mucin carrying the type 1 chain determinants were not significantly different in cancer patients as compared with patients with nonmalignant disorders. However, the degree of glycosylation of the antigen, as assessed by its solubility in perchloric acid, showed significant differences; i.e., the mucin antigen carrying 2----6 sialylated Lea determinant in the sera of patients with nonmalignant disorders had the highest carbohydrate/protein ratio, followed by the mucin carrying the same determinant in the sera of cancer patients. Mucin antigen carrying 2----3 sialylated Lea antigen or 2----3, 2----6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio among the four groups tested. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients (P less than 0.05). This finding is in contrast to previous findings on the mucin antigens carrying the type 2 chain determinant (R. Kannagi et al., Cancer Res., 46: 2619-2626, 1986), in which the mucin antigen in cancer patients was found to have a much higher carbohydrate/protein ratio than that carrying the same antigenic determinants in patients with nonmalignant disorders.
Similar articles
- Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine.
Kannagi R, Fukushi Y, Tachikawa T, Noda A, Shin S, Shigeta K, Hiraiwa N, Fukuda Y, Inamoto T, Hakomori S, et al. Kannagi R, et al. Cancer Res. 1986 May;46(5):2619-26. Cancer Res. 1986. PMID: 3008996 - Lewisx- and sialylated Lewisx-related antigen expression in human malignant and nonmalignant colonic tissues.
Itzkowitz SH, Yuan M, Fukushi Y, Palekar A, Phelps PC, Shamsuddin AM, Trump BF, Hakomori S, Kim YS. Itzkowitz SH, et al. Cancer Res. 1986 May;46(5):2627-32. Cancer Res. 1986. PMID: 3516383 - Humoral immune responses to tumor-associated carbohydrate antigens.
Lloyd KO. Lloyd KO. Semin Cancer Biol. 1991 Dec;2(6):421-31. Semin Cancer Biol. 1991. PMID: 1725731 Review. - [Biological function of cancer-associated carbohydrate antigens].
Kannagi R. Kannagi R. Nihon Rinsho. 1996 Jun;54(6):1551-9. Nihon Rinsho. 1996. PMID: 8691608 Review. Japanese.
Cited by
- Preliminary Analysis of the Glycolipid Profile in Secondary Brain Tumors.
Serb AF, Novaconi C, Georgescu M, Puiu M, Dema A, Onulov R, Sisu E. Serb AF, et al. Biomed Res Int. 2022 Nov 22;2022:4293172. doi: 10.1155/2022/4293172. eCollection 2022. Biomed Res Int. 2022. PMID: 36457344 Free PMC article. - BGN/TLR4/NF-B Mediates Epigenetic Silencing of Immunosuppressive Siglec Ligands in Colon Cancer Cells.
Huang HC, Cai BH, Suen CS, Lee HY, Hwang MJ, Liu FT, Kannagi R. Huang HC, et al. Cells. 2020 Feb 9;9(2):397. doi: 10.3390/cells9020397. Cells. 2020. PMID: 32050430 Free PMC article. - Clinicopathological and prognostic significance of sialyl Lewis X overexpression in patients with cancer: a meta-analysis.
Liang JX, Liang Y, Gao W. Liang JX, et al. Onco Targets Ther. 2016 May 24;9:3113-25. doi: 10.2147/OTT.S102389. eCollection 2016. Onco Targets Ther. 2016. PMID: 27307752 Free PMC article. - Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.
De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. De Divitiis C, et al. World J Gastroenterol. 2014 Nov 7;20(41):15049-59. doi: 10.3748/wjg.v20.i41.15049. World J Gastroenterol. 2014. PMID: 25386053 Free PMC article. Review. - Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers.
Senda M, Ito A, Tsuchida A, Hagiwara T, Kaneda T, Nakamura Y, Kasama K, Kiso M, Yoshikawa K, Katagiri Y, Ono Y, Ogiso M, Urano T, Furukawa K, Oshima S, Furukawa K. Senda M, et al. Biochem J. 2007 Mar 15;402(3):459-70. doi: 10.1042/BJ20061118. Biochem J. 2007. PMID: 17123352 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous